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Background: Sodium metabisulfite is commonly used as preservative in foods but can oxidize to sulfite radicals
initiating molecular oxidation. Ghrelin is a peptide hormone primarily produced in the stomach and has anti-
inflammatory effects in many organs. This study aimed to assess endogenous omega-3 (n-3) and omega-6 (n-6)
polyunsaturated fatty acids (PUFAs) in rat peripheral organs following sodium metabisulfite treatment and determine
the possible effect of ghrelin on changes in n-6 inflammatory pathway.
Methods: Male Wistar rats included in the study were allowed free access to standard rat chow. Sodium metabisulfite
was given by gastric gavage and ghrelin was administered intraperitoneally for 5 weeks. Levels of arachidonic
acid (AA, C20:4n-6), dihomo-gamma-linolenic acid (DGLA, C20:3n-6), eicosapentaenoic acid (EPA, C20:5n-3) and
docosahexaenoic acid (DHA, C22:6n-3) in liver, heart and kidney tissues were determined by an optimized multiple
reaction monitoring (MRM) method using ultra fast-liquid chromatography (UFLC) coupled with tandem mass
spectrometry (MS/MS). Cyclooxygenase (COX) and prostaglandin E2 (PGE2) were measured in tissue samples to
evaluate changes in n-6 inflammatory pathway.
Results: Omega-6 PUFA levels, AA/DHA and AA/EPA ratio were significantly increased in liver tissue following
sodium metabisulfite treatment compared to controls. No significant change was observed in heart and kidney
PUFA levels. Tissue activity of COX and PGE2 levels were also significantly increased in liver tissue of sodium
metabisulfite treated rats compared to controls. Ghrelin treatment decreased n-6 PUFA levels and reduced COX
and PGE2 levels in liver tissue of sodium metabisulfite treated rats.
Conclusion: Current results suggest that ghrelin exerts anti-inflammatory action through modulation of n-6 PUFA
levels in hepatic tissue.
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Sodium metabisulfite (Na2S2O5) is one of the leading
food preservatives and is used for the preservation of
pastries, cheese, beverages, ground beef, margarine, fruit,
sausages, sweets and fish [1]. It serves to prevent growth
of bacteria, mould, yeast and controls enzymatic and
non-enzymatic browning [2]. When ingested, Na2S2O5
reacts with water leading to the generation of bisulfite
(HSO3
−), sulfur dioxide (SO2) and sulfite (SO3
2−) [3].* Correspondence: mutayaslan@akdeniz.edu.tr
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unless otherwise stated.Thus, Na2S2O5 is termed as a “sulfating agent” because
it releases SO2.
Ingested Na2S2O5 is absorbed in the gastrointestinal
tract and is distributed to all tissues via systemic circula-
tion [4]. Many organs are protected against the harmful
effects of sulfite by the detoxifying sulfite oxidase, which
oxidizes sulfite to sulfate [5]. Exogenous sulfites are pre-
sented to the liver’s biotransformation system for pro-
cessing and elimination and their oxidation is diffusion
limited [6]. However, when in excess amount they can
stress the detoxification capability of the liver or be par-
tially processed and accumulate in the liver and adipose
tissue [2]. This can lead to increased liver stores of thesehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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shown that sulfite oxidation can cause oxidative damage
in organs such as liver and kidney [7].
Previous studies have shown that long-term in vivo ex-
posure to sulfite aerosols induces inflammatory reactions
[8,9] and that alveolar macrophages incubated with sul-
fite generate significantly increased amounts of arachi-
donic acid (AA) and AA-derived eicosanoids synthesized
by cyclooxygenase (COX), such as prostaglandin E2
(PGE2) and platelet aggregating thromboxane B2 (TXB2)
[10]. Indeed, different response patterns induced by
sulfur-related compounds may be due to changes in the
generation and release of inflammatory mediators which
play an important role in eliciting reactions in tissues
and cells. In vitro studies provide evidence that sulfite is
able to activate alveolar macrophages by lipid mediators
such as platelet-activating factor (PAF) and leukotriene
B4 (LTB4) [11,12].
Ghrelin is an acylated peptide that stimulates the re-
lease of growth hormone (GH) from the anterior pituit-
ary via binding to the GH secretagogue receptor (GHS-
R) [13]. Circulating ghrelin is produced primarily in the
stomach by X/A-like cells of the fundic glands, while the
remainder originates in X/A-like cells of the small intes-
tine [14]. Growth hormone secretagogue receptors are
present in tissues other than the hypothalamus and pitu-
itary, which indicates that ghrelin has other effects in
addition to stimulating the release of growth hormone
[15]. Indeed, besides the stimulation of GH release,
ghrelin has also been described to have beneficial effect
on gastrointestinal [16], cardiovascular [17], reproduct-
ive [18] and coagulation systems [19]. Recent studies
have revealed that ghrelin may be an anti-inflammatory
agent in many organs such as the rat ovary [20] and
brain [21].
Although studies have shown that sulfite exposure
leads to increased arachidonic acid levels in alveolar
macrophages, changes in liver, heart and kidney PUFA
levels following Na2S2O5 ingestion has not been investi-
gated. This study was designed to determine changes in
endogenous PUFA levels in rat peripheral organs and in-
vestigate whether ghrelin attenuates inflammatory path-
ways induced by Na2S2O5.
Materials and methods
Preparation of animals
All experimental protocols conducted on rats were per-
formed in accordance with the standards established by
the Institutional Animal Care and Use Committee at
Akdeniz University Medical School. Male Wistar rats
weighing 350–450 g were housed in stainless steel cages
and were allowed free access to water and standard rat
chow (Korkutelim Yem, Antalya, Turkey) containing
6.05% crude fat which included linoliec acid, linolenicacid, saturated fatty acids and monounsaturated fatty
acids. Animals were maintained at 12 h light–dark cycles
and a constant temperature of 23 ± 1°C at all times. Rats
were randomly divided into four experimental groups
which included control (n = 8); rats treated with sodium
metabisulfite (Na2S2O5) (n = 10); rats treated with ghrelin
(n = 10); rats treated with Na2S2O5 + ghrelin (n = 10).
Control group received 1 ml/kg/day distilled water via
gavage and 1 ml/kg/day saline via intraperitoneal injec-
tion as vehicle for 35 days. Sodium metabisulfite treated
animals were given freshly prepared Na2S2O5 (100 mg/
kg/day) solution via gastric gavage for 5 weeks as previ-
ously described [22]. We have shown that Na2S2O5 is
efficiently absorbed at the given dose when adminis-
tered via intragastric gavage and significantly increases
plasma S-sulfonate levels [23]. Rat Ghrelin (GenScript,
NJ, USA) was dissolved in distilled water (1 mg/ml) and
stored at −20°C until the time of preparation for adminis-
tration. Immediately before administration, ghrelin was di-
luted with 0.9% physiologic saline to a final concentration
of 0.1 mg/ml. Ghrelin was given intraperitoneally (ip) at
adose of 20 μg/kg for 35 days as previously described [24].
We have previously shown that the given dose and dur-
ation of ghrelin has protective effects against oxidative tis-
sue injury and apoptosis in rats [24].
Electrospray ionization mass spectrometry
Standards for arachidonic acid (AA, C20:4n-6), dihomo-
gamma-linolenic acid (DGLA, C20:3n-6), eicosapenta-
enoic acid (EPA, C20:5n-3) and docosahexaenoic acid
(DHA, C22:6n-3) were purchased from Sigma-Aldrich
(St. Louis MO, USA). Deuterium labeled AA-d8 internal
standard (5,6,8,9,11,12,14,15-AA-d8) was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Solu-
tions of AA, DGLA, EPA, DHA and AA-d8 standards
were prepared in analytical grade methanol (Merck,
Darmstadt, Germany). An optimized multiple reaction
monitoring (MRM) method was developed using ultra-
fast liquid chromatography (UFLC) coupled with tandem
mass spectrometry (MS/MS). A UFLC system (LC-
20 AD UFLC XR, Shimadzu Corporation, Japan) was
coupled to a LCMS-8040 triple quadrupole mass spec-
trometer (Shimadzu Corporation, Japan). Chromato-
graphic separations were carried out using Inertsil HPLC
column (ODS-4, 2.1 × 100 mm, 3 μm; GL Sciences Inc.
Tokyo, Japan) maintained at 40°C. DHA, EPA, AA and
DGLA were separated using a gradient elution with a flow
rate of 0.45 ml/min. Mobile phase solvent A was 10 mM
ammonium acetate (Sigma-Aldrich, St. Louis, MO,
USA) in water and solvent B was acetonitrile (Sigma-
Aldrich, St. Louis, MO, USA). Gradient program was
solvent B, 70% (0 min), 90% (3 min), 100% (3.01-4 min)
and 70 % (4.01-8 min). MRM transitions and responses
were automatically optimized for individual compounds
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ESI-MS mode the precursor and product m/z values
for AA, DHA, EPA, DGLA and AA-d8 are given in the
results section. Responses to AA, DHA, EPA and
DGLA were optimized to a linear calibration range
from 100 ng/ml to 30 ug/ml and a sample analysis time
of 8 minutes.
Sample preparation for LC-MS/MS
Samples were prepared for LC-MS/MS analysis via a
modified protocol as previously described [25,26]. All
tissues were weighed and homogenized in ice-cold
50 mmol/L sodium phosphate buffer (pH 7.4). Homoge-
nates were centrifuged (10,000 g for 15 min at 4°C) and
supernatants were stored at −80°C. Briefly, in a glass test
tube, 200 μl tissue supernatant was added to 200 μl AA-
d8 internal standard solution. 1 ml of acetonitril/37%
hydrochloric acid (Cayman, Ann Arbor, MI, USA) was
added to the mixture in a 4:1 v/v. Tubes were capped
with reusable teflon liner screw caps and samples were
hydrolyzed by incubating at 90°C for 2 hours in a heat-
ing block (VLM, Bielefeld, Germany). After cooling
down to room temperature, fatty acids were extracted
with 2 ml of hexane. Samples were vortex-mixed for
20 seconds, left at room temperature for 5 minutes and
centrifuged at 3000 rpm for 1 minute. The upper phase
containing free fatty acids were transferred to glass tubes
and evaporated at room temperature under a constant
stream of nitrogen with height adjustable gas distribu-
tion unit (VLM, Bielefeld, Germany). Fatty acids were
dissolved in 200 μl methanol–water (180:20, v/v) filtered
via 0,2 μm polytetrafluoroethylene (PTFE) syringe filters
(Whatman, GE Healthcare Bio-Sciences, Pittsburgh,
USA) and transferred to autosampler vials (Vertical
Chromatography, Nonthaburi, Thailand).
Measurement of liver cyclooxygenase activity
Liver tissues were weighed and homogenized in 0.1 M
ice-cold Tris–HCl buffer at pH 7.8 containing 1 mM
EDTA. Tissue homogenates were centrifuged at 10,000 g
for 15 minutes at 4°C and supernatants were kept at −80°C
until assayed. Cyclooxygenase (COX) activity was mea-
sured using a COX activity assay kit (Cayman Chemical,
Cat No: 760151 Ann Arbor, MI, USA) according to manu-
facturer’s instructions. The COX activity assay kit mea-
sures enzyme activity colorimetrically by monitoring the
appearance of oxidized N,N,N’,N’-tetramethyl-p-phenyl-
enediamine (TMPD) at 590 nm. One unit of enzyme ac-
tivity was defined as the amount of enzyme that caused
the oxidation of 1 nmol of TMPD per minute at 25°C.
Measurement of liver Prostaglandin E2
Prostaglandin E2 (PGE2) was measured in tissue samples
by a commercial enzyme immunoassay test kit (CaymanChemical, Cat No: 514010 Ann Arbor, MI, USA) accord-
ing to manufacturer’s instructions. Liver tissues were
weighed and homogenized in 0.1 M ice-cold phosphate
buffer at pH 7.4 containing 1 mM EDTA and 10 μM
indomethacin. Tissue homogenates were centrifuged at
10,000 g for 15 minutes at 4°C and supernatants were
kept at −80°C until assayed. Briefly, PGE2 present in the
sample competes with acetylcholinesterase-labeled PGE2
antibody for binding sites on a goat polyclonal anti-
mouse antibody. Following a wash to remove unbound
materials, a substrate solution is added to the wells to
determine the bound enzyme activity. The color devel-
opment is stopped, and the absorbance is read at
412 nm. The intensity of the color is inversely propor-
tional to the concentration of PGE2 in the sample. A
standard curve of absorbance values of known PGE2
standards was plotted as a function of the logarithm of
PGE2 standard concentrations (pg/ml) using the Graph-
Pad Prism Software program for windows version 5,03.
(GraphPad Software Inc). PGE2 concentrations in the
samples were calculated from their corresponding ab-
sorbance values via the standard curve.
Protein measurements
Protein concentrations were measured at 595 nm by a
modified Bradford assay using Coomassie Plus reagent
with bovine serum albumin as a standard (Pierce Chem-
ical Company, Rockford, IL).
Statistical analysis
Data were analyzed using Sigma Stat (version 2.03) stat-
istical software for Windows, and a P value <0.05 was
considered statistically significant. Statistical analysis for




We have recorded the body weight of all animals during
the 5 week experimental period. We have seen a signifi-
cant increase in the weight of animals treated with
ghrelin. This data is shown in Figure 1. There was a sig-
nificant increase in the weight of animals treated ghrelin.
Weight increase (mean ± SD) measured in experimental
groups were as follows: Control (n = 8), 26,00 ± 12,27;
Na2S2O5 (n = 10), 37,50 ± 9,79; Ghrelin (n = 10), 58,33 ±
12,25 and Na2S2O5 +Ghrelin (n = 10), 54,44 ± 14,88 grams.
ESI-MS spectra
The precursor and product m/z values for analyzed
PUFAs were as follows: DGLA (C20: 3n6), precursor
m/z: 304.80, product m/z: 59.00, 260.70; AA (C20: 4n6),





















Figure 1 Weight increase during the 5 week experimental
period. C, control; S, sodium metabisulfite; G, ghrelin; S + G, sodium
metabisulfite + ghrelin. All values are mean ± SD. Statistical analysis
was performed by one way analysis of variance and all pairwise
multiple comparisons were via Tukey test. *, p < 0.05 vs. C and G.
Figure 2 ESI-MS spectra. A) Representative negative ion mode spectra of
Eicosapentaenoic acid; DHA, Docosahexaenoic acid. B) Tandem mass spect
Ercan et al. Lipids in Health and Disease  (2015) 14:7 Page 4 of 9(C20:5n3), precursor m/z: 301.10, product m/z: 59.10,
256.70; DHA (C22: 6n3): precursor m/z: 327.10, prod-
uct m/z: 59.10, 283.20; AA-d8, precursor m/z: 311.10,
product m/z: 59.10, 97.90, 267.10. Figure 2A shows rep-
resentative negative ion mode spectra obtained from
measured PUFAs. As shown in Figure 2A, retention
time of time of EPA (C20: 5n3), DHA (C22: 6n3), AA
(C20: 4n6), AA-d8 and DGLA (C20: 3n6) was 1.869,
2.131, 2.391, 2.329 and 2.911 minutes, respectively.
Figure 2B shows tandem mass spectra obtained by
collision-induced dissociation of precursor ions. The
m/z values of product ions correspond to endogenous
C20: 5n3, C20: 4n6, C20: 3n6 and C22: 6n3. The
deuterium-labeled internal standard fatty acid peak is
indicated at m/z values 267.1.DGLA, Dihomo-gamma-linolenic acid; AA, Arachidonic acid; EPA,
ra.
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Levels of endogenous PUFAs measured in liver, heart
and kidney tissues are given in Tables 1, 2 and 3,
respectively. DGLA and AA levels were increased in
liver tissue following sodium metabisulfite treatment
compared to control and ghrelin treated groups. No
significant change was observed in liver EPA and DHA
amount following sodium metabisulfite treatment. Ghrelin
treatment significantly decreased DGLA and AA levels
in sodium metabisulfite treated rats. AA/DHA and AA/
EPA ratio were significantly increased in liver tissue fol-
lowing sodium metabisulfite treatment compared to
control, ghrelin and Na2S2O5 + ghrelin groups (Table 1).
No significant change was observed in heart and kidney
PUFA levels, AA/DHA and AA/EPA ratio (tables 2 and
3, respectively). Box plot graph data of AA (C20:4n-6),
DGLA (C20:3n-6), EPA (C20:5n-3) and DHA (C22:6n-
3) distribution in liver of all experimental groups are
shown in Figure 3. The boundary of the box closest to
zero indicates the 25th percentile, the line within the
box marks the median, and the boundary of the box
farthest from zero indicates the 75th percentile. Whis-
kers above and below the box indicate the 90th and
10th percentiles.Liver cyclooxygenase activity
Total COX activity, as shown in Figure 4A, was signifi-
cantly increased in liver tissue following sodium metabi-
sulfite treatment when compared to control and ghrelin
treated groups. Ghrelin treatment significantly decreased
total COX activity in Na2S2O5 treated rats. Total COX
activity (mean ± SD) measured in experimental groups
were as follows: Control, 3.06 ± 0.77; Na2S2O5, 7.43 ± 0.
29; Ghrelin, 3.72 ± 1.47 and Na2S2O5 + Ghrelin, 5.87 ±
0,90 U/mg protein.Table 1 Analysis of polyunsaturated fatty acids in liver tissue
Parameter Control (n = 8) Na2S2O5 (n = 10
DGLA (C20:3n6) 3.73 ± 1.26 9.44 ± 2.32a
AA (C20:4n6) 17.73 ± 7.74 90.44 ± 32.63c,d
EPA (C20:5n3) 0.85 ± 0.50 1.11 ± 0.47
DHA (C22:6n3) 10.14 ± 3.29 11.96 ± 7.45
AA/DHA 3.35 ± 1.17 9.33 ± 3.02f
AA/EPA 27.66 ± 14.21 87.66 ± 37.24f
Values are expressed as mg fatty acid/g tissue protein. Data are reported as mean ±
AA, Arachidonic acid; EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid. Stati
multiple comparisons via Tukey test or Kruskal-Wallis One Way Analysis of Variance
ap ≤ 0.001 Na2S2O5 vs. control, ghrelin, Na2S2O5 + ghrelin.
bp < 0.05 Na2S2O5 + ghrelin vs. Ghrelin.
cp < 0.001 Na2S2O5 vs. control, ghrelin.
dp = 0.002 Na2S2O5 vs. Na2S2O5 + ghrelin.
ep = 0.002 Na2S2O5 + ghrelin vs. control.
fp < 0.05 Na2S2O5 vs. control, ghrelin, Na2S2O5 + ghrelin.Liver prostaglandin E2 levels
Liver PGE2 levels, as shown in Figure 4B, was signifi-
cantly increased in liver tissue following sodium metabi-
sulfite treatment when compared to control, ghrelin, and
Na2S2O5 + ghrelin treated groups. PGE2 levels (mean ±
SD) measured in experimental groups were as follows:
Control, 45,64 ± 16,91; Na2S2O5, 105,56 ± 29,90; Ghrelin,
43,40 ± 16,68 and Na2S2O5 + Ghrelin, 64,09 ± 6,96 pg/mg
protein.
Discussion
To the best of our knowledge, this study is the first to
measure endogenous DGLA (C20:3n-6), AA (C20:4n-6),
DHA (C22:6n-3) and EPA (C20:5n-3) levels in rat per-
ipheral organs following Na2S2O5 ingestion. This study
makes the novel observation that ingestion of 100 mg/
kg/day Na2S2O5 for 5 weeks results in significantly in-
creased n-6 PUFA levels, AA/DHA and AA/EPA ratio in
the liver and leads to significantly increased tissue activ-
ity of COX and PGE2 levels. It also shows that ghrelin
decreases n-6 PUFA levels and reduces COX and PGE2
levels in liver tissue of sodium metabisulfite treated rats.
The dose of sulfite administered in this study was de-
termined with reference to our previous studies de-
signed to investigate the effects of high level of sulfite
intake [22-24]. The amount of ingested sulfite is usually
expressed as SO2 equivalents (SDE) and with reference
to the reported theoretical yield of 67.39 % SO2 from
Na2S2O5 [27,28], the given dose of 100 mg Na2S2O5/
kg/day was equivalent to 67.39 mg/kg/day SO2. The Joint
Expert Committee in the World Health Organization
(WHO) has established an acceptable daily intake (ADI)
level for sulfites which is reported to be 0.7 mg/kg body
weight, expressed as SO2 [28]. Considering that many
foods such as sausage, dried fruit, beer and wine contain
sulfite, the ADI level can easily be exceeded. It is possible) Ghrelin (n = 10) Na2S2O5 + Ghrelin (n = 10)
3.65 ± 1.15 5.98 ± 2.52b
29.43 ± 9.09 54.89 ± 10.57b,e
1.12 ± 0.38 1.13 ± 0.60
11.42 ± 4.46 9.74 ± 2.56
3.05 ± 1.02 4.01 ± 0.71
26.60 ± 7.67 34.36 ± 7.64
SD. Na2S2O5, sodium metabisulfite; DGLA, Dihomo-gamma-linolenic acid;
stical analysis was performed by one way analysis of variance with all pairwise
on Ranks with all pairwise multiple comparison procedures by Dunn's Method.
Table 2 Analysis of polyunsaturated fatty acids in heart tissue
Parameter Control (n = 8) Na2S2O5 (n = 10) Ghrelin (n = 10) Na2S2O5 + Ghrelin (n = 10)
DGLA (C20:3n6) 0.15 ± 0.06 0.18 ± 0.06 0.16 ± 0.08 0.14 ± 0.07
AA (C20:4n6) 2.56 ± 1.02 2.95 ± 0.56 2.46 ± 1.10 2.28 ± 1.01
EPA (C20:5n3) 0.07 ± 0.02 0.06 ± 0.03 0.05 ± 0.04 0.05 ± 0.02
DHA (C22:6n3) 2.27 ± 0.98 2.65 ± 0.92 2.81 ± 1.46 1.81 ± 0.98
AA/DHA 1.16 ± 0.16 1.09 ± 0.18 0.90 ± 0.13 1.24 ± 0.30
AA/EPA 49.52 ± 12.76 44.50 ± 14.70 47.57 ± 10.43 54.11 ± 17.80
Values are expressed as mg fatty acid/g tissue protein. Data are reported as mean ± SD. Na2S2O5, sodium metabisulfite; DGLA, Dihomo-gamma-linolenic acid;
AA, Arachidonic acid; EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid. Statistical analysis was performed by one way analysis of variance or Kruskal-Wallis
One Way Analysis of Variance on Ranks.
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erages in a single day or meal [2,29].
Hepatic oxidation of exogenous sulfite is diffusion lim-
ited [6]. That is to say the liver metabolizes a constant
fraction of sulfite it receives, but a limited amount will
pass through the organ and enter the systemic circula-
tion [2]. Mammalians contain sulfite oxidase (SOX),
which catalyzes the oxidative detoxification of sulfite in
order to protect the cells from sulfite toxicity. It was
shown that rats have a 10–20-fold greater SOX activity
than humans [5]. Ingested sulfites also undergo a nonen-
zymatic reaction with disulfide bonds generating gluta-
thione S-sulfonate [4] and thus, plasma S-sulfonate level
is commonly used as a biomarker of ingested sulfite
[30]. The rhesus monkey and the rabbit accumulate
plasma S-sulfonates much more readily than rat, while
the mouse produce little under the same test conditions
[31]. Unlike rodents, plasma S-sulfonate levels can be
readily detected under basal condition in humans [32]. It
was previously shown by our group that Na2S2O5 is effi-
ciently absorbed at the given dose (100 mg/kg/day) when
administered via intragastric gavage and significantly in-
creases plasma S-sulfonate levels in rats [23,33].
The observed increase in liver n-6 PUFA levels, AA/
DHA and AA/EPA ratio support previous studies which
have shown that long-term in vivo exposure to sulfite
aerosols induces inflammatory reactions [34] and that
alveolar macrophages incubated with sulfite generateTable 3 Analysis of polyunsaturated fatty acids in kidney tiss
Parameter Control (n = 8) Na2S2O5 (n = 10
DGLA (C20:3n6) 1.00 ± 0.47 1.18 ± 0.60
AA (C20:4n6) 10.70 ± 5.39 12.69 ± 5.51
EPA (C20:5n3) 0.45 ± 0.19 0.48 ± 0.13
DHA (C22:6n3) 1.71 ± 0.97 2.13 ± 0.91
AA/DHA 6.91 ± 2.76 6.04 ± 1.44
AA/EPA 24.03 ± 7.01 27.84 ± 13.80
Values are expressed as mg fatty acid/g tissue protein. Data are reported as mean ±
AA, Arachidonic acid; EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid. Stati
One Way Analysis of Variance on Ranks.significantly increased amounts of arachidonic acid (AA)
and AA-derived eicosanoids [10]. Mammalians can pro-
duce many fatty acids except the two essential PUFAs
which include linoleic acid (LA, C18:2n6) and alpha-
linolenic acid (ALA, C18:3n3). Linoleic acid is the
precursor of n-6 series of PUFAs including DGLA
(C20:3n-6) and AA (C20:4n-6) while ALA is the pre-
cursor of n-3 series of PUFAs which include DHA
(C22:6n-3) and EPA (C20:5n-3). Competition between n-6
and n-3 fatty acids occurs in the production of eicosanoids
by stereospecific lipid-oxidizing enzymes cylooxygenase
(COX) and lipoxygenase (LOX) [35]. Eicosanoids, de-
rived mainly from AA (C20:4n-6) are key mediators
and regulators of inflammation. They include prosta-
glandins (PGs), thromboxanes (TXs) and leukotrienes
(LTs) [36]. Eicosanoids derived from n-3 PUFAs such as
EPA, C20:5n-3) have anti-inflammatory properties, at-
tributed to their ability to inhibit the formation of n-6
PUFA-derived eicosanoids [36]. Resolvins and protec-
tins generated from EPA (C20:5n-3) and DHA (C22:6n-
3) display potent antiinflammatory properties and are
recognized in the resolution of inflammation [37].
Hence, increased AA to EPA or AA to DHA ratio indi-
cates more precursor for the synthesis of highly inflam-
matory eicosanoids.
We have seen that the given dose of sodium metabi-
sulfite treatment caused no significant change in PUFA
levels in heart and kidney tissues of rats while itue
) Ghrelin (n = 10) Na2S2O5 + Ghrelin (n = 10)
0.76 ± 0.17 0.77 ± 0.57
7.11 ± 1.94 9.18 ± 6.32
0.36 ± 0.11 0.43 ± 0.19
1.60 ± 1.27 1.30 ± 0.34
6.13 ± 1.19 5.60 ± 0.41
20.69 ± 4.27 20.50 ± 3.95
SD. Na2S2O5, sodium metabisulfite; DGLA, Dihomo-gamma-linolenic acid;
stical analysis was performed by one way analysis of variance or Kruskal-Wallis
Figure 3 Distribution of polyunsaturated fatty acids in the liver of experimental groups. C, control; S, sodium metabisulfite; G, ghrelin;
S + G, sodium metabisulfite + ghrelin. DGLA, Dihomo-gamma-linolenic acid; AA, Arachidonic acid; EPA, Eicosapentaenoic acid; DHA,
Docosahexaenoic acid.
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in the liver. This discrepancy is likely to result from the
metabolism of ingested sulfite. As stated previously, ex-
ogenous sulfites are presented to the liver’s biotrans-
formation system for processing and elimination and
their oxidation is diffusion limited [6]. However, when in
excess amount they can stress the detoxification capabil-
ity of the liver or be partially processed and accumulate
in the liver [2]. This can lead to increased liver stores of
these toxic compounds and cause tissue injury.
Activity of COX, the initial enzyme of prostaglandin
synthesis was also measured in liver tissue following so-























Figure 4 Liver cyclooxygenase and prostaglandin E2 levels. A) Liver cy
S + G, sodium metabisulfite + ghrelin. All values are mean ± SD. Statistical a
multiple comparisons were via Tukey test. *, p < 0.001 vs. C and G. **, p = 0
Statistical analysis was performed by one way analysis of variance and all p
and S + G.rate-limiting enzyme in the production of prostanoids
from arachidonic acid. Research has showed that the
COX/prostanoid pathway is activated in hepatic diseases
and liver stress reaction, such as alcoholic liver disease
[38], liver fibrogenesis [39], viral hepatitis C [40] and
liver ischemic/reperfusion injury [41] causing liver dam-
age manifested as inflammation, necrosis and fatty liver.
In agreement with increased liver COX activity, we have
also measured significantly increased liver PGE2 levels
following sodium metabisulfite ingestion. Arachidonic
acid is a precursor of PGE2 synthesis and PGE2. It is
produced during inflammatory responses and mediates a





















clooxygenase activity. C, control; S, sodium metabisulfite; G, ghrelin;
nalysis was performed by one way analysis of variance and all pairwise
.005 vs. S. B) Liver prostaglandin E2 levels. All values are mean ± SD.
airwise multiple comparisons were via Tukey test. *, p < 0.001 vs. C, G
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acid (ASA) is a COX inhibitor and different from other
cyclooxygenase inhibitors it enhances the formation of
anti-inflammatory and pro-resolution lipoxins derived
from arachidonic acid as well as resolvins from n-3
PUFAs such as docosahexaenoic acid (DHA). In a recent
study, the effect of ASA was examined on murine dex-
tran sodium sulfate-induced colitis. The results showed
that ASA reduced the severity of dextran sodium
sulfate-induced colitis and increased the formation of
anti-Inflammatory lipid mediators [43].
We have seen that ghrelin decreased both n-6 PUFA
levels and attenuated n-6 inflammatory pathway in liver
tissue following high level of sulfite intake. These obser-
vations are in agreement with studies reporting the
beneficial effect of ghrelin on the gastrointestinal system
[16] and support the role of ghrelin as an anti-
inflammatory agent in many organs such as the rat ovary
[20] and brain [21].
Ghrelin has been proposed as an antioxidant agent re-
cently in several studies [18,21]. Obay at al. demon-
strated that ghrelin prevents lipid peroxidation and
decrease of antioxidant enzyme activities against penty-
lenetetrazole induced oxidative stress in erythrocytes,
liver and brain in rats [21]. Moreover, several studies
showed that, ghrelin significantly increases the activity
of antioxidant enzymes such as GPx, SOD and CAT and
decreases the concentration of malondialdehyde, a prod-
uct of lipid peroxidation [18]. The antioxidant property of
ghrelin was also demonstrated by attenuation of oxidative
stress in gastric mucosa triggered by Na2S2O5 [24].
Ghrelin is a neuropeptide that can be produced by im-
mune cells especially under inflammatory conditions
[44]. Anti-inflammatory neuropeptides emerge as a new
strategy to manage inflammation-based diseases. In
mammals, several lines of evidence indicate that ghrelin
stimulates corticosteroid release in rats [45]. Ghrelin can
also signal through the activation of cAMP/protein kin-
ase A (PKA) pathway, which is considered as an im-
munosuppressive signal [46]. Through the elevation of
intracellular cAMP, it can down-regulate the activation
of several transduction pathways and transcription fac-
tors essential for the transcriptional activation of most of
the inflammatory cytokines [44]. Observed findings
herein support the anti-inflammatory actions of ghrelin
reported previously.
Conclusion
In summary, we report that liver AA (C20:4n-6), DGLA
(C20:3n-6), AA/DHA and AA/EPA ratio are significantly
increased in rats following high level of sulfite intake
and that sulfite ingestion leads to significantly increased
liver activity of COX and PGE2 levels. We also show
that ghrelin decreases n-6 PUFA levels and reducesCOX and PGE2 levels in liver tissue of sodium metabi-
sulfite treated rats. Further studies are needed to clarify
mechanisms by which ghrelin regulates the n-6 inflam-
matory pathway in liver tissue.
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